EBV-targeted cell therapy after stem cell transplant
Part of Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had a stem cell transplant from a donor.
- You have high EBV levels in your blood (over 1000 copies per mL on two tests, or over 10,000 copies per mL on one test).
- You are up and able to do daily activities (Karnofsky score of 70 or higher).
- Your organs (kidneys, liver, blood counts) are working well enough.
- You do not have active graft-versus-host disease (GVHD) needing strong steroids, or other serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
This study tests whether a single dose of rituximab (a targeted antibody therapy) given after a donor stem cell transplant can reduce dangerous levels of the EBV virus in the blood. It aims to prevent a serious complication called PTLD (lymphoma-like disease) that sometimes occurs after transplant.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Hear when a new EBV-DNA Viremia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.